Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
1(25.0%)
Early Phase 1
1(25.0%)
4Total
N/A(2)
Phase 1(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05157061Not ApplicableCompleted

GOS to Reduce Symptom Severity in IBS

Role: lead

NCT02796872Not ApplicableCompleted

The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)

Role: lead

NCT01004120Phase 1Completed

Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults

Role: lead

NCT01303484Early Phase 1Completed

The Effect of Prebiotic B-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People

Role: lead

All 4 trials loaded